• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Fractional-dose vaccination offers long lasting protection against yellow fever

byCaitlyn HuiandDeepti Shroff Karhade
November 29, 2018
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This ten-year follow-up study of a randomized controlled trial suggested that intradermal administration of one fifth of the yellow fever vaccine could provide long-term immunity for at least ten years.

2. The participants in this study who received the fractionated dose of yellow fever vaccine did not require any booster vaccines to maintain immunity during the study period.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Yellow fever results in acute hemorrhagic disease, which is caused by a virus transmitted through mosquitoes. This infectious disease is endemic in many tropical and subtropical areas, especially in parts of Africa and South America. Prophylaxis is the mainstay of treatment and prevention for yellow fever, as there is not currently a cure beyond supportive care for those who contract the disease. As the yellow fever vaccine is challenging to make in large doses, many countries do not have adequate stores of the vaccine in case of an outbreak. Therefore, the authors of this study examined whether fractional-dose vaccination could confer long-term immunity. Generally, they observed that fractional-dose vaccination offered long lasting protection against yellow fever. Study limitations included that only 48% of the participants from the original trial then participated in this follow-up study. Furthermore, the authors acknowledged that the study did not compare methods of vaccination with the yellow fever vaccine, such as evaluating subcutaneous versus intradermal injection.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Fractional-Dose Yellow Fever Vaccination — Advancing the Evidence Base

In-Depth [randomized controlled trial follow-up]: The authors of this study conducted a ten-year follow up of a randomized controlled non-inferiority trial, which included about 48% of the original study participants. This study was based in the Netherlands; a total of 75 participants provided a blood sample for the study. The authors assessed virus-neutralizing antibodies in patients who received the fractionated dose of yellow fever vaccine compared to the full dose through a plaque reduction neutralization test. The secondary end point of the study was the geometric mean titer (GMT) of virus-neutralizing antibodies in each group. The mean age of vaccination for both groups was 26 and both had the same mean time since primary vaccination. Generally, the authors observed that 98% of the fractionated-dose group had protective levels of yellow fever-neutralizing antibodies (95% CI, 89% to 100%) compared to 97% (CI, 97% to 100%) in the standard-dose control group. Furthermore, similar GMTs were observed between the fractional and standard-dose groups.

RELATED REPORTS

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

 Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: vaccineyellow fever
Previous Post

American College of Physicians releases principles to guide patient partnership in health care

Next Post

Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial

RelatedReports

Clinical practice guidelines linked to improved bronchiolitis outcomes
Infectious Disease

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

May 13, 2022
Preterm infants responsive to PCV13 vaccine
Infectious Disease

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

May 10, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

April 12, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

AD26.COV2.S vaccine provides protection against Covid-19

March 7, 2022
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

The ODYSSEY OUTCOMES trial: Alirocumab associated with reduced ischemic events after acute coronary syndrome

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
  • Endovascular abdominal aortic aneurysm repair may be associated with higher overall mortality and complications compared to open repair
  • Meditation may provide medical benefit for various health outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.